Cerluten vs Testagen

CNS-targeted peptide complex that modulates neuronal gene expression. Shown in Russian clinical studies to improve memory consolidation, attention, and protect against neurodegeneration.

Cerluten is a synthetic short peptide classified as a Khavinson-class bioregulator targeted at cerebral and central nervous system tissue, investigated for neuroprotective and anti-aging properties in neuronal cell populations through proposed gene expression regulatory mechanisms. Like other Khavinson bioregulator peptides, cerluten is proposed to reach target neuronal cells via amino acid transporter uptake — including proton-coupled oligopeptide transporters (POT) and large amino acid transporters (LAT) — and to modulate transcriptional activity in aging or damaged neural tissue. Published research on Khavinson-class ultrashort peptides has characterized intracellular transport via POT and LAT carriers and demonstrated gene expression regulatory effects across multiple tissue types, providing the class-level mechanistic framework within which cerluten's neuronal effects are proposed. Cerluten has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals. Cerluten dosing and respiratory applications Cerluten is classified as a bronchial tissue bioregulator in the Khavinson peptide research tradition, proposed to act on bronchial epithelial cells via amino acid transporter uptake and modulate gene expression related to respiratory tissue maintenance and oxidative stress response in aging airways. Preclinical and observational research in Eastern European clinical settings has examined cerluten in contexts of chronic bronchitis, age-related decline in respiratory function, and COPD support, with proposed mechanisms including anti-inflammatory gene regulation and bronchial epithelial cell cytoprotection. Standard Khavinson-class dosing protocols use oral capsule formulations in 10–20 day cycles at 5–10mg per cycle (divided doses), followed by rest intervals — consistent with the gene-regulatory rather than continuous-receptor-occupancy mechanism proposed for this peptide class. Independent peer-reviewed clinical trial evidence specific to cerluten is limited; efficacy data comes primarily from Khavinson Institute publications and observational reports. Cerluten is available from specialty Eastern European supplement and peptide vendors and is not approved by the FDA or EMA as a pharmaceutical. It is distinct from Chonluten, which targets lung parenchyma rather than bronchial epithelial tissue.

Khavinson-class tetrapeptide bioregulator derived from testicular tissue; proposed to modulate gene expression in Leydig and Sertoli cells; investigated for age-related testicular function decline

Testagen is a synthetic tetrapeptide and Khavinson-class peptide bioregulator derived from testicular tissue, investigated for regulatory effects on testicular cell function and age-related reproductive hormone decline. Like other Khavinson-class bioregulators, testagen is proposed to act as a short regulatory peptide that modulates gene expression in target organ cells — in this case, testicular Leydig cells responsible for testosterone synthesis and Sertoli cells that support spermatogenesis. The Khavinson bioregulator model posits that short peptides derived from specific tissues preferentially interact with chromatin regulatory elements in homologous tissues, restoring expression of age-downregulated genes and partially reversing organ-level functional decline associated with aging. Research interest in testagen centers on age-associated decline in testicular function, including reduced Leydig cell activity and the associated decline in testosterone biosynthesis that characterizes male aging. Preclinical studies have examined testagen-class peptides for effects on reproductive hormone levels, testicular histomorphology, and markers of gonadal function in aged animal models. Testagen is part of the broader Khavinson bioregulator research program that has also characterized thymalin (thymus), cortagen (cardiovascular/neural), cartalax (cartilage), and pinealon (pineal gland) as organ-specific regulatory peptides. Testagen benefits investigated in preclinical research include support for testosterone biosynthesis pathways, maintenance of Leydig cell populations, and preservation of testicular tissue architecture with aging. These effects are proposed to occur through epigenetic regulatory mechanisms rather than direct hormonal supplementation, distinguishing bioregulator peptides from exogenous testosterone replacement. Testagen is classified as a research compound with no regulatory approval in any jurisdiction. No human clinical trials have established safety or efficacy for testicular support, testosterone augmentation, or reproductive function endpoints. Research protocols have examined testagen primarily via subcutaneous injection, with oral delivery also studied in bioregulator research contexts.